title: Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique.
abstract: Helicobacter pylori infection continues to play a key role in gastric diseases. Colonization of the gastric mucosa with the bacterium invariably results in the development of chronic gastritis and subsets of patients have a progression of the chronic gastritis to either ulcer or cancer. Epidemiological evidence indicates that the proportion of all gastric cancers attributable to H. pylori infection, and hence potentially preventable upon elimination of this risk factor, is somewhere in the range of 60% to 90%. This portends significant benefit in terms of morbidity and mortality, not least in populations with high prevalence of H. pylori infection coupled with high incidence of gastric cancer. The effect of prophylactic H. pylori eradication on gastric cancer incidence in humans remains unknown, however. Results from randomized trials are eagerly awaited, but availability of strong conclusive results may take many years. A growing number of studies show considerable variation in risk for gastric cancer development, depending on H. pylori strain type and the genetic predisposition of the host. There is also a remote possibility that elimination of the infection may have adverse health implications (e.g., antibiotic resistance), and therefore "simple" risk stratification and targeted chemoprevention is required. Based on "in depth" evidence presented at this workshop, the majority of the scientific task force favored a search-and-treat strategy in first-degree relatives of gastric cancer patients and an overwhelming majority felt that a more general screen-and-treat strategy should be focused in the first instance on a population with a high incidence of H. pylori-associated diseases.
authors.affiliation: Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Malfertheiner
authors.forename: Pentti
authors.initials: P
authors.lastname: Sipponen
authors.forename: Michael
authors.initials: M
authors.lastname: Naumann
authors.forename: Paul
authors.initials: P
authors.lastname: Moayyedi
authors.forename: Francis
authors.initials: F
authors.lastname: Mégraud
authors.forename: Shu-Dong
authors.initials: SD
authors.lastname: Xiao
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sugano
authors.forename: Olof
authors.initials: O
authors.lastname: Nyrén
mesh_terms: D000818:Animals; D005757:Gastritis, Atrophic / Q000209:etiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000235:genetics; D016480:Helicobacter pylori; D006801:Humans; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000517:prevention & control*